跳至主要内容
临床试验/NCT04278950
NCT04278950Unknown不适用

Povidone-Iodine Rinses as an Adjuvant Therapy Post-Operatively: A Double-Blind Randomized Controlled Trial

St. Paul's Hospital, Canada0 个研究点目标入组 100 人开始时间: 2020年2月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
100
主要终点
Modified Lund-Kennedy endoscopic scores

研究概览

简要总结

Povidone Iodine solution is a nasal antiseptic. Its application has been shown to be clinically safe, tolerable and effective against bacteria and fungi associated with chronic rhinosinusitis.

The purpose of this study is determining the effectiveness of PVP-I in comparison to a placebo for post-operative refractory CRS patients in a randomized controlled trial.

详细描述

Background and scientific rationale Chronic rhinosinusitis (CRS) is an inflammatory condition of the paranasal sinuses affecting millions of patients, resulting in billions of dollars being spent annually in associated health care costs. Biofilm has been implicated in chronic rhinosinusitis recalcitrant to appropriate medical therapy and well-executed endoscopic sinus surgery. The presence of biofilm results in patients having worse postoperative symptoms, recurrent infections, and persistent inflammation. Biofilms are bacterial or fungi communities surrounded by an extracellular polysaccharide matrix, which facilitates attachment to mucosa, survival, protection and proliferation. This configuration allows for resistance to innate host defenses and resistance to antibiotic therapy.

Iodine bound to the synthetic carrier polymer povidone (PVP-I), has been used in wound care for several decades. The microbial activity of iodine has been thought to be facilitated through several oxidative mechanisms of action and has been shown to be effective against a wide variety of pathogens. These mechanisms include inhibition of vital bacterial cellular mechanisms, denaturation of enzymes in the respiratory chain, and oxidation of key structures in cell membranes. Previously, PVP-I-containing dressings have demonstrated complete destruction of biofilm bacteria. As well, using PVP-I as a gargle has shown bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Enterococcus faecium, among others, more so than other antimicrobials.

Use of antibiotics immediately after surgery, saline irrigation, and debridement in the office are relatively consistent post-surgical procedures for CRS patients. However, resistance to topical antibiotics such as mupirocin, fusidic acid, and gentamicin has been demonstrated in recent years. Furthermore, out of a survey of 265 otolaryngologists, it has been found that most physicians (86.8%) prescribe antibiotics following surgery, with the majority (63.9%) only taking cultures on occasion and therefore using broad-spectrum antibiotics despite issues of overuse. In contrast, resistance to PVP-I has not been documented to date and is therefore an attractive alternative in post-surgical management of CRS patients.

There is a paucity of published data on the use of iodine after sinus surgery to treat biofilm.The purpose of this study is determining the effectiveness of PVP-I in comparison to a placebo for post-operative refractory CRS patients in a randomized controlled trial.

Primary Objective:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 19 years or older
  • Undergoing FESS at St. Paul's Hospital or False Creek Surgical Centre

排除标准

  • Patients with sinonasal tumors.
  • Patients who previously used PVP-I rinses - Patients with autoimmune diseases affecting the upper airway
  • eg Systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis etc.
  • Immuno-compromised patients, and patients with impairment in mucociliary function
  • (e.g., cystic fibrosis, Kartagener syndrome)
  • Hypersensitivity to iodine
  • History of thyroid disorders including thyroid cancer, hyperthyroidism and hypothyroidism
  • Use of medications for thyroid disorders including thyroxine and carbimazole
  • Pregnancy
  • Patients unable to speak English.

研究组 & 干预措施

Poviodine Iodine Solution

Active Comparator

Patients will be randomized into this arm will be provided with 0.10% PVP-I (0.01% available iodine). Patients will be instructed to dilute 2.5mL of the betadine (unmarked bottles) into a 240mL bottle of saline and rinse once per day.

干预措施: Povidone-Iodine (Drug)

Placebo Poviodine Iodine Solution

Placebo Comparator

Patients will be randomized into this arm will be provided with a placebo PVP-I solution. Patients will be instructed to dilute 2.5mL of the placebo PVP-I (unmarked bottles) into a 240mL bottle of saline and rinse once per day.

干预措施: Placebos (Drug)

结局指标

主要结局

Modified Lund-Kennedy endoscopic scores

时间窗: 6 months

This score is based on the endoscopic assessment of polyps, edema, and discharge and are each given score 0-2. A higher score indicates a worse outcome.

Cultures and Sensitivity

时间窗: 6 months

Assess whether there is positive growth of bacteria or fungi.

次要结局

  • Blood test(6 months)
  • SNOT-22(6 months)
  • Saccharin test(6 months)
  • Sniffin' Stick smell test(6 months)

研究者

发起方
St. Paul's Hospital, Canada
申办方类型
Other
责任方
Principal Investigator
主要研究者

Amin Javer

Clinical Professor

St. Paul's Hospital, Canada

相似试验